According to a recent LinkedIn post from ThinkCyte, the company used its presence at SLAS 2026 in Boston to spotlight its Ghost Cytometry platform and VisionSort technology for label-free, AI-driven cell analysis. The post points readers to two new scientific posters focused on phenotyping and sorting phagocytosing immune cells and on morphometric profiling related to cellular senescence.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights ThinkCyte’s emphasis on high-speed, label-free cell sorting combined with real-time AI analysis, positioning these capabilities as tools to deepen phenotypic insights in drug discovery and cell biology workflows. The availability of downloadable posters and invitations to book meetings with product specialists suggest an active effort to convert conference interest into commercial and collaboration opportunities.
For investors, the focus on VisionSort and Ghost Cytometry at a major industry conference may indicate continued investment in platform validation and thought leadership within flow cytometry and regenerative medicine research markets. If these technologies gain traction with academic and biopharma customers, ThinkCyte could strengthen its competitive position in AI-enabled cell analysis, potentially supporting future revenue growth tied to instruments, software, and related services.